These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 29599363)
1. Effects of ω-3 Fatty Acid Supplementation in Patients with Bile Duct or Pancreatic Cancer Undergoing Chemotherapy. Abe K; Uwagawa T; Haruki K; Takano Y; Onda S; Sakamoto T; Gocho T; Yanaga K Anticancer Res; 2018 Apr; 38(4):2369-2375. PubMed ID: 29599363 [TBL] [Abstract][Full Text] [Related]
2. [Current status and future directions of chemotherapy for pancreatic cancer]. Furuse J Nihon Shokakibyo Gakkai Zasshi; 2013 Dec; 110(12):2060-5. PubMed ID: 24305093 [No Abstract] [Full Text] [Related]
3. Effects of an enteral nutrient-rich therapy with omega-3 fatty acids in patients with unresectable or recurrent biliary tract cancer or pancreatic cancer during chemotherapy: a case-control study. Abe K; Uwagawa T; Hamura R; Shirai Y; Yasuda J; Furukawa K; Shiozaki H; Onda S; Gocho T; Ikegami T Med Oncol; 2022 Apr; 39(5):66. PubMed ID: 35478069 [TBL] [Abstract][Full Text] [Related]
5. Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study. Le N; Vinci A; Schober M; Krug S; Javed MA; Kohlmann T; Sund M; Neesse A; Beyer G Digestion; 2016; 94(4):222-229. PubMed ID: 28030863 [TBL] [Abstract][Full Text] [Related]
6. Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX. McBride A; Bonafede M; Cai Q; Princic N; Tran O; Pelletier C; Parisi M; Patel M Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1153-1160. PubMed ID: 28795609 [TBL] [Abstract][Full Text] [Related]
7. Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX. Kim GP; Parisi MF; Patel MB; Pelletier CL; Belk KW Expert Rev Clin Pharmacol; 2017 May; 10(5):559-565. PubMed ID: 28286977 [TBL] [Abstract][Full Text] [Related]
8. Prolonged response to liposomal irinotecan in a patient with stage IV pancreatic/bile duct cancer previously treated with FOLFIRINOX and gemcitabine plus nab-paclitaxel. Surinach A; Phung T; Abdul-Rahim O; Khushman M Curr Oncol; 2020 Apr; 27(2):e222-e225. PubMed ID: 32489272 [TBL] [Abstract][Full Text] [Related]
9. First-line treatment for advanced pancreatic cancer. Kothari N; Saif MW; Kim R JOP; 2013 Mar; 14(2):129-32. PubMed ID: 23474553 [TBL] [Abstract][Full Text] [Related]
10. [Response in a case of inoperable bile duct cancer treated by combined chemotherapy of S-1 and gemcitabine]. Akiyama N; Ayata S; Maruyama Y; Tsukada Y Gan To Kagaku Ryoho; 2010 Aug; 37(8):1591-3. PubMed ID: 20716894 [TBL] [Abstract][Full Text] [Related]
11. Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis. Takumoto Y; Sasahara Y; Narimatsu H; Akazawa M JAMA Netw Open; 2022 Jan; 5(1):e2145515. PubMed ID: 35099549 [TBL] [Abstract][Full Text] [Related]
12. Treatment patterns and outcomes in pancreatic cancer: Retrospective claims analysis. Doleh Y; Lal LS; Blauer-Petersen C; Antico G; Pishvaian M Cancer Med; 2020 May; 9(10):3463-3476. PubMed ID: 32212262 [TBL] [Abstract][Full Text] [Related]
13. Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospective analysis. El Rassy E; Assi T; El Karak F; Ghosn M; Kattan J Clin Res Hepatol Gastroenterol; 2017 Mar; 41(2):e26-e28. PubMed ID: 28215539 [No Abstract] [Full Text] [Related]
14. Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3). Go SI; Lee SC; Bae WK; Zang DY; Lee HW; Jang JS; Ji JH; Kim JH; Park S; Sym SJ; Yang Y; Jeon SY; Hwang IG; Oh SY; Kang JH Eur J Cancer; 2021 Nov; 157():21-30. PubMed ID: 34464782 [TBL] [Abstract][Full Text] [Related]
15. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V; Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442 [TBL] [Abstract][Full Text] [Related]
16. Modified FOLFIRINOX for Locally Advanced and Metastatic Pancreatic Cancer Patients Resistant to Gemcitabine and S-1 in Japan: A Single Institutional Experience. Umemura A; Nitta H; Sasaki A; Takahara T; Hasegawa Y; Wakabayashi G Hepatogastroenterology; 2014 May; 61(131):814-20. PubMed ID: 26176079 [TBL] [Abstract][Full Text] [Related]
17. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma. Ellenrieder V; König A; Seufferlein T Digestion; 2016; 94(1):44-9. PubMed ID: 27438590 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of S-1 in second-line chemotherapy after nab-paclitaxel plus gemcitabine for patients with advanced pancreatic cancer. Iede K; Yamada T; Kato R; Ueda M; Tsuda Y; Nakashima S; Ohta K; Matsuyama J; Ikenaga M; Tominaga S Cancer Rep (Hoboken); 2020 Apr; 3(2):e1215. PubMed ID: 32672000 [TBL] [Abstract][Full Text] [Related]
19. Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study. Pointet AL; Tougeron D; Pernot S; Pozet A; Béchade D; Trouilloud I; Lourenco N; Hautefeuille V; Locher C; Williet N; Desrame J; Artru P; Soularue E; Le Roy B; Taieb J Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):295-301. PubMed ID: 31607641 [TBL] [Abstract][Full Text] [Related]